People · Operator
Named in public records as an officer, director or promoter · active 2015–2024 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Endolytix Technology, Inc. | — | Pharmaceuticals | Series A | $21.3M | $25.0M | 2024 |
| FB2 Services, Inc. | — | Biotechnology | Series A | $7.6M | $276.0M | 2015 |
Richard Snyder at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Richard Snyder on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Anderson | 1 | 21 |
| RON ZWANZIGER | 1 | 6 |
| Gary Magnant | 1 | 5 |
| John Patterson | 1 | 4 |
| Tim Martin | 1 | 4 |
| Gabrielle Bernstein | 1 | 1 |
| Jason Holder | 1 | 1 |
| Ruoxi Hu | 1 | 1 |
| Westley Nolin | 1 | 1 |
| Westly Nolin | 1 | 1 |
| Rouxi Hu | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.